MK-6837-001 is a Phase 1 open-label, multicenter clinical trial evaluating MK-6837, an investigational agent developed by Merck Sharp & Dohme LLC, as both monotherapy and in combination with other anticancer therapies in participants with advanced or metastatic solid tumors.
The trial is designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of MK-6837. Given the study's keywords referencing PD-1/PD-L1 pathways, MK-6837 likely functions as an immunotherapeutic agent — possibly a small molecule modulator of the PD-1/PD-L1 axis or a novel checkpoint pathway inhibitor.
| Attribute |
Value |
| Phase |
Phase 1 |
| Status |
Active, not recruiting (verified December 2025) |
| Sponsor |
Merck Sharp & Dohme LLC |
| NCT Number |
NCT06460961 |
| Study ID |
MK-6837-001 / 6837-001 |
| Enrollment |
168 participants (estimated) |
| Age Range |
18 years and older |
| Sex |
All |
| Start Date |
July 14, 2024 |
| Primary Completion |
July 13, 2027 (estimated) |
| Completion Date |
July 13, 2027 (estimated) |
| Study Type |
Interventional |
| Allocation |
Non-randomized |
| Intervention Model |
Parallel |
| Masking |
None (open-label) |
| Primary Purpose |
Treatment |
- Design: Open-label, dose-escalation and dose-expansion Phase 1
- Arms: Parallel design with monotherapy and combination therapy cohorts
- Treatment Cycles: Each cycle is 21 days
- Duration: Up to approximately 35 months of treatment
MK-6837 is an investigational agent from Merck's oncology pipeline. Based on the study's inclusion of PD-1/PD-L1/PD-L2 keywords, MK-6837 likely targets the programmed cell death protein 1 (PD-1) pathway or a related immunomodulatory mechanism.
The PD-1/PD-L1 axis is a critical immune checkpoint:
- PD-1 (Programmed Cell Death Protein 1) is an inhibitory receptor expressed on activated T cells
- PD-L1 (Programmed Death-Ligand 1) is a transmembrane protein often upregulated on tumor cells and antigen-presenting cells
- When PD-1 binds PD-L1, it suppresses T cell activation and enables tumor immune evasion
Therapeutic blockade of this pathway (e.g., pembrolizumab, nivolumab as monoclonal antibodies) has revolutionized cancer treatment. MK-6837 may represent a next-generation approach — potentially a small molecule inhibitor of PD-1/PD-L1 interactions, an oral alternative to intravenous antibodies, or a novel bispecific agent.
Advanced and metastatic solid tumors frequently exploit PD-L1 upregulation to evade immune detection. By targeting this pathway, MK-6837 aims to:
- Restore T cell-mediated cytotoxicity against tumor cells
- Promote durable responses through immune memory
- Potentially combine synergistically with other anticancer modalities
The trial studies MK-6837 both alone and in combination with other agents, reflecting the clinical reality that:
- Combination approaches can overcome resistance mechanisms
- Immunotherapy + chemotherapy/radiation can enhance antigen release
- Sequential or concurrent targeting of multiple pathways may improve outcomes
See PD-1/PD-L1 Checkpoint Inhibitors in Cancer Immunotherapy for more on this therapeutic class.
- Histologically or cytologically confirmed solid tumor by pathology report that is advanced or metastatic
- Human Immunodeficiency Virus (HIV)-infected participants must have well-controlled HIV on Antiretroviral Therapy (ART)
- Hepatitis B Surface Antigen (HBsAg) positive participants are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation
- Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening
- Has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from any adverse events due to cancer therapeutics administered more than 4 weeks earlier
- History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
- Clinically significant cardiovascular disease
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
- Prior immunotherapy discontinued due to Grade 3 or higher immune-related adverse event (except endocrine disorders treatable with replacement therapy) or due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
- Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities requiring corticosteroids
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
- Known additional malignancy that is progressing or required active treatment within the past 2 years
- Known active Central Nervous System (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years (except replacement therapy)
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Active infection requiring systemic therapy
- History of allogeneic tissue/solid organ transplant
Primary Endpoint: Number of participants who experience one or more dose-limiting toxicities (DLTs).
The following events are considered DLTs unless clearly due to underlying disease or extraneous causes:
- Grade 4 neutropenia lasting >7 days
- Grade 3 or higher thrombocytopenia associated with clinically significant bleeding (regardless of duration)
- All Grade 3 or higher nonhematologic toxicities (with specified exceptions)
- Any abnormality that results in drug-induced liver injury
- Febrile neutropenia Grade 3 or 4
- Prolonged delay (>2 weeks) in initiating treatment after the first 21 days due to intervention-related toxicity
- Any intervention-related toxicity that causes the participant to discontinue intervention during the first 21 days
- Grade 5 toxicity
Time Frame: Cycle 1 (up to approximately 21 days); each cycle is 21 days.
This DLT assessment is standard in Phase 1 oncology trials to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
Secondary Endpoints (Safety):
- Number of participants who experience one or more adverse events (AEs)
- Number of participants who discontinue study intervention due to an AE
Time Frame: Up to approximately 35 months.
The trial employs a parallel design with multiple arms:
| Arm |
Description |
Status |
| Experimental (Monotherapy) |
MK-6837 alone |
Active |
| Experimental (Combination) |
MK-6837 + other anticancer agent(s) |
Active |
Phase 1 oncology trials typically use dose-escalation designs (e.g., 3+3, rolling-six, or Bayesian designs) to identify the optimal dose. The monotherapy arm likely serves as the lead-in for dose determination, followed by expansion cohorts and combination arms.
Standard Phase 1 objectives include:
- Characterizing MK-6837 plasma pharmacokinetics (Cmax, AUC, half-life, clearance)
- Assessing target engagement biomarkers
- Evaluating preliminary antitumor activity (objective response rate, disease control rate)
The PD-1/PD-L1 axis is one of the most validated targets in modern oncology:
- PD-L1 expression is a predictive biomarker for response to checkpoint inhibitors
- Blockade can produce durable responses in multiple tumor types (melanoma, lung, bladder, kidney, etc.)
- Combination with chemotherapy, radiation, or targeted therapy can enhance efficacy
- Small molecule inhibitors may offer advantages over antibodies (oral bioavailability, improved tumor penetration, lower immunogenicity)
MK-6837 represents Merck's continued investment in immunotherapy, building on the success of pembrolizumab (Keytruda). Potential differentiators include:
- Novel mechanism beyond existing checkpoint inhibitors
- Small molecule format enabling different dosing and scheduling
- Possible activity in tumors resistant to existing checkpoint blockade
See Cancer Immunotherapy: Checkpoint Inhibition for broader context.
While this trial is an oncology study, immune checkpoint pathways have relevance in neurodegenerative disease research:
- PD-1/PD-L1 in Neuroinflammation: The PD-1 pathway modulates microglial activation and neuroimmune responses. Preclinical studies have explored whether checkpoint modulation affects neuroinflammation in Alzheimer's and Parkinson's disease models[@sah2021].
- Cancer-Neurodegeneration Paradox: Epidemiologic studies have noted inverse associations between certain cancers and neurodegenerative disease risk, possibly involving shared signaling pathways.
- Immune System Cross-Talk: Understanding immunomodulatory mechanisms has implications beyond oncology.
For these reasons, MK-6837 may be of interest to the NeuroWiki community as a novel immunomodulatory agent, even though its current indication is solid tumors.
Merck (MSD outside the US) has one of the most established oncology portfolios in the industry:
| Drug |
Mechanism |
Indication |
| Pembrolizumab (Keytruda) |
Anti-PD-1 mAb |
Multiple solid tumors |
| MK-2870 (SKB264) |
TROP2 ADC |
Solid tumors |
| MK-1084 |
PD-L1/TGF-beta bifunctional |
Solid tumors |
| MK-6837 |
Novel immunotherapy |
Advanced solid tumors |
MK-6837 represents Merck's next wave of immunomodulatory agents beyond the established anti-PD-1 antibody franchise.